ECCO’26

ECCO Abstract Awards

Abstract submitters may participate in the application process for the following awards

Top 16 DOP Awards

IIS Abstract Award

Y-ECCO Abstract Award

Group picture of the winners of the DOP Awards

In the center: the winners of the Top 16 DOP Awards

Winners of the Top 16 DOP Awards 2026

DOP006

Ileocaecal resection versus infliximab for ileal Crohn’s disease: 10-year follow-up of the LIR!C trial.
Anouck Haanappel, Amsterdam, The Netherlands

DOP018

Histologic Signatures as Predictors of Intestinal Barrier Dysfunction in IBD: Integration with Endoscopic and Molecular Markers.
Irene Zammarchi, Cork, Ireland

DOP026

HLA-DRB1*01:03 is associated with perianal Crohn’s disease phenotype and severity.
Eathar Shakweh, London, United Kingdom

DOP028

Treat-to-target optimization is effective on endoscopic and histologic outcomes in a real-life cohort of ulcerative colitis – the TACTIC-UC Study.
Giuseppe Privitera, Rozzano, Italy

DOP044

Prevalence and factors associated with inflammatory bowel disease (IBD) activity during pregnancy: updated data from the Dumbo registry.
Susana Tomás, Madrid, Spain

DOP049

Transcriptomic profiling reveals divergent molecular pathways underlying Ulcerative Colitis disease activity and prognostic severity.
Anna-Teresa D’hooghe, Leuven, Belgium

DOP058

Efficacy and safety of picankibart in patients with moderately to severely active ulcerative colitis: a randomised, double-blind, placebo-controlled phase 2 trial.
Shanshan Huang, Guangzhou, China

DOP066

Pharmacokinetics and transcriptomic analysis reveal the molecular signature of mucosal healing in patients with Acute Severe Ulcerative Colitis treated with infliximab (PROTOS).
Robert Battat, Quebec, Leuven, Canada

DOP078

Development of a bioengineered 3D model of gut barrier defence against Candida albicans invasion and inflammasome activation in Crohn’s Disease.
Sean Carlson, London, United Kingdom

DOP084

Ustekinumab and vedolizumab in the treatment of fistulising Crohn’s disease: a propensity score-matched analysis from the prospective Persistence Australian National Inflammatory Bowel Disease Cohort (PANIC5) study.
John Chetwood, Sydney, Australia

DOP097

Discovery and external validation of machine learning-derived blood gene signatures for predicting endoscopic disease severity in Ulcerative Colitis.
John P Thomas, London, United Kingdom

DOP100

Combination treatment with adalimumab and partial enteral nutrition compared with adalimumab monotherapy in adults with active Crohn’s disease: The BIOPIC study.
Bernadette White, Glasgow, Guangzhou, United Kingdom

DOP111

Integrated Immune and Molecular Profiling Identifies Inflammatory Bowel Disease Lesions at Risk for Advanced Neoplasia.
Konstantin Bräutigam, London, United Kingdom

DOP121

Patients with IBD Are at Increased Risk of Metabolic Dysfunction–Associated Steatotic Liver Disease, Independent of Classic Metabolic Risk Factors.
Dror Shouval, Petah Tiqwa, Israel

DOP135

Bowel damage and disability in Crohn’s disease in the first year after diagnosis -results from the CROCO study.
Joana Revés, Loures, Portugal

DOP144

Escherichia coli shapes intestinal B-cell responses and influences susceptibility to Inflammatory Bowel Disease.
Sophia Adlkirchner, Adlkirchner,Germany

Group picture of the winners of the IIS Abstract Awards

In the center, from left to right: Florian Tran, Jonas Halfvarson– the winners of the IIS Abstract Award

Best Investigator-Initiated Study (IIS) report submitted – IIS Abstract Award

The Clinical Research Committee of ECCO (ClinCom) wants to stimulate the development of high-quality Investigator-Initiated Studies (IIS) in IBD and to improve the quality of IBD clinical studies in Europe through education. In 2027, awards will be given to the 2 best congress abstracts reporting on clinical studies set up by investigators (preferably multi-centre) submitted for the ECCO Congress. Note: Studies conducted by industry will not be eligible for this award.

The winners for 2026 are

OP13: Florian Tran, Kiel, Germany
OP04: Jonas Halfvarson, Örebro, Sweden

Responsible Committee

Clinical Research Committee of ECCO (ClinCom)

Prize

Free registration for the ECCO Congress 2027

Number of awards

Who can apply for the 2027 award

ECCO Members reporting on clinical studies set up by investigators in their abstracts. Note: ECCO Membership fee 2026 must be paid up until the abstract submission deadline.

How to apply

In case you are not an ECCO Member yet please register for ECCO Membership 2026
Log in to the ECCO'27 Abstract submission system
At the beginning of the submission process please indicate if your abstract is qualified for the IIS Abstract Award
Please pay careful attention to the general guidelines for abstract submission
Upload your abstract for the ECCO Congress 2027
Notification of the author in the beginning of December 2026
Announcement at the ECCO'27 Congress

In the center, from left to right: Dan Lintao, Olle Grannö, John P Thomas, Angela Sanzo Machuca, Luke Hanna – five winners of the Y-ECCO Abstract Award

Y-ECCO Abstract Award

The Young ECCO (Y-ECCO) encourages Y-ECCO Members to submit their abstract and share their research with the ECCO Community. In 2027, awards will be given to the 5 best-ranked abstracts along with a free congress registration for the following year.